- Trial phase
- Approved
- Time to market
- Already approved and on the market, US FDA approval recorded 2017-08-03, with a further FDA approval/label expansion recorded 2021-06-10
- Why 3/10
- No hard, dated binary catalyst in the next ~12 months: Mavyret is already approved and marketed (FDA approval catalysts recorded 2017-08-03 and 2021-06-10), the defining binary has passed, and the drug is a minor, mature part of a mega-cap, the recorded 2017 approval moved ABBV just +0.4% (1-day) and the 2021 label expansion +1.25% (1-day), so this one drug is unlikely to drive meaningful share-price movement.
Maviret/Mavyret is a mature, already-approved hepatitis C franchise inside a $253/share mega-cap; there is no near-term drug-specific binary to trade, so it should not be treated as a catalyst stock. Watch ABBV quarterly earnings (Q2 2026 reported 2026-07-31) for the direction of the shrinking HCV line, and the company's larger pipeline readouts (e.g., ABBV-951 Parkinson's, Bimatoprost SR) if you want an ABBV catalyst.
Price Chart
Executive Summary
Maviret (US brand Mavyret) is AbbVie's oral hepatitis C treatment, confirmed by SecBot's local FDA catalyst ledger as an ABBV drug approved in August 2017 and expanded via a June 2021 FDA approval event. It is a fully commercialized product with no pending regulatory decision, and the recorded stock reactions to its two approval events were small (+0.4% and +1.25% one-day moves for ABBV), underscoring that it is a modest part of a large-cap portfolio.
How It Works
Maviret is an all-oral, fixed-dose combination of two antiviral drugs (glecaprevir, a protease inhibitor, and pibrentasvir, an NS5A inhibitor) that attack the hepatitis C virus at two different points to stop it from multiplying; standard labeling positions it as an 8–16 week curative regimen across HCV genotypes, including in patients with compensated cirrhosis.
Trial Status
Marketed product; SecBot's FDA catalyst ledger records two fda_approval events for ABBV/MAVYRET (2017-08-03 initial approval, 2021-06-10 label expansion). No active Mavyret clinical-trial records appear in SecBot's Phase 2/3 pipeline data, consistent with a commercial-stage drug.
The Two-Sided Case
Upcoming Catalysts
- None for Mavyret itself, no scheduled regulatory decision, label expansion, or pivotal readout identified in the next ~12 months.
- ABBV-level events that could move the stock but are unrelated to Mavyret: quarterly earnings (Q2 2026 reported 2026-07-31; Q3 2026 later in the year), pending Phase 3 readouts for ABBV-951 (Parkinson's) and Bimatoprost SR (glaucoma), and any HCV-line commentary on earnings calls.
- Watch for any generics/pricing headlines in the HCV space (could not be checked externally this session).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AbbVie Inc. 8-K ABBV ·Originating report